Clinical Trial Update: Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Obicetrapib in patients with familial hypercholesterolemia on maximally tolerated lipid-modifying therapy has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipidemia
• Hyperlipoproteinemia

Drugs mentioned

• Obicetrapib (obicetrapib)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Dyslipidemias, High Cholesterol | Phase 3 | Status: COMPLETED | Results posted: 2025-06-11